Has the U.K. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 20.2x which is lower than its 3-year average PE of 24.8x. The industry is trading close to its 3-year average PS ratio of 3.4x.

Which industries have driven the changes within the U.K. Healthcare industry?

There are no additional sub-industries under this industry.

U.K. (FTSE) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 18 Aug 2026	UK£290.0b	UK£92.7b	UK£14.4b	21.1x	20.2x	3.1x
Thu, 16 Jul 2026	UK£308.4b	UK£91.6b	UK£15.7b	19x	19.6x	3.4x
Sat, 13 Jun 2026	UK£323.3b	UK£92.0b	UK£15.8b	17.9x	20.4x	3.5x
Mon, 11 May 2026	UK£315.7b	UK£91.3b	UK£15.7b	17.6x	20.1x	3.5x
Wed, 08 Apr 2026	UK£354.4b	UK£91.1b	UK£15.7b	19.7x	22.6x	3.9x
Fri, 06 Mar 2026	UK£351.1b	UK£90.9b	UK£15.7b	21x	22.4x	3.9x
Sun, 01 Feb 2026	UK£325.6b	UK£88.6b	UK£14.5b	23.7x	22.5x	3.7x
Tue, 30 Dec 2025	UK£325.0b	UK£89.3b	UK£14.6b	21.8x	22.3x	3.6x
Thu, 27 Nov 2025	UK£331.3b	UK£90.2b	UK£14.7b	21.7x	22.5x	3.7x
Sat, 25 Oct 2025	UK£296.9b	UK£88.1b	UK£11.8b	20.5x	25.2x	3.4x
Mon, 22 Sep 2025	UK£271.9b	UK£87.6b	UK£11.7b	18.7x	23.2x	3.1x
Wed, 20 Aug 2025	UK£280.0b	UK£87.5b	UK£11.7b	21.6x	23.9x	3.2x
Fri, 18 Jul 2025	UK£256.2b	UK£86.7b	UK£10.7b	25.7x	24x	3x
Sun, 15 Jun 2025	UK£274.4b	UK£86.2b	UK£10.6b	27.2x	25.9x	3.2x
Tue, 13 May 2025	UK£259.4b	UK£87.7b	UK£10.8b	26.1x	24.1x	3x
Thu, 10 Apr 2025	UK£239.7b	UK£88.1b	UK£9.8b	27.3x	24.5x	2.7x
Sat, 08 Mar 2025	UK£293.8b	UK£87.8b	UK£9.6b	29.2x	30.6x	3.3x
Mon, 03 Feb 2025	UK£275.1b	UK£87.2b	UK£9.1b	30.8x	30.4x	3.2x
Wed, 01 Jan 2025	UK£224.6b	UK£75.4b	UK£7.8b	31.3x	28.8x	3x
Fri, 29 Nov 2024	UK£226.5b	UK£74.9b	UK£7.7b	32.1x	29.3x	3x
Sun, 27 Oct 2024	UK£247.0b	UK£72.6b	UK£9.1b	29.9x	27.2x	3.4x
Tue, 24 Sep 2024	UK£252.7b	UK£71.5b	UK£8.9b	37.8x	28.3x	3.5x
Thu, 22 Aug 2024	UK£274.4b	UK£72.2b	UK£9.0b	41x	30.5x	3.8x
Sat, 20 Jul 2024	UK£258.0b	UK£70.9b	UK£9.5b	35.2x	27.3x	3.6x
Mon, 17 Jun 2024	UK£267.2b	UK£71.6b	UK£9.6b	31.5x	27.9x	3.7x
Wed, 15 May 2024	UK£271.9b	UK£71.9b	UK£9.6b	36.7x	28.3x	3.8x
Fri, 12 Apr 2024	UK£246.1b	UK£71.0b	UK£9.7b	33.5x	25.3x	3.5x
Sun, 10 Mar 2024	UK£235.2b	UK£70.1b	UK£9.7b	31x	24.3x	3.4x
Tue, 06 Feb 2024	UK£234.7b	UK£69.3b	UK£9.6b	34.9x	24.4x	3.4x
Thu, 04 Jan 2024	UK£240.0b	UK£69.1b	UK£10.7b	35.7x	22.4x	3.5x
Sat, 02 Dec 2023	UK£227.9b	UK£69.0b	UK£10.7b	34x	21.3x	3.3x
Mon, 30 Oct 2023	UK£229.1b	UK£70.8b	UK£10.4b	54x	22.1x	3.2x
Wed, 27 Sep 2023	UK£249.8b	UK£70.7b	UK£10.4b	56.6x	24.1x	3.5x
Fri, 25 Aug 2023	UK£236.5b	UK£69.2b	UK£10.2b	53.5x	23.2x	3.4x


GB Market	-1.36%
Healthcare	-3.49%
Pharma	-3.67%
Pharma	-3.67%

Company	Last Price	7D	1Y	Valuation
SAR Sareum Holdings	UK£0.28	21.7% +UK£6.9m	21.7%	PB32.5x
STX Shield Therapeutics	UK£0.044	14.3% +UK£5.9m	-32.3%	PS1.3x
EAH ECO Animal Health Group	UK£1.01	4.1% +UK£2.7m	37.4%	PE31.2x
POLB Poolbeg Pharma	UK£0.087	4.1% +UK£2.6m	190.0%	PB7.7x
FUM Futura Medical	UK£0.0044	29.4% +UK£581.3k	-95.3%	PS1.5x

Announcement • 1h

AstraZeneca Demonstrates Statistically Significant and Clinically Meaningful Improvements with TAGRISSO Plus Savolitinib in Saffron Phase III Trial

AstraZeneca showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or amplification and had progressed on prior treatment with TAGRISSO. Third-generation EGFR-tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for patients with EGFRm NSCLC. However, one in three patients’ tumors will develop MET overexpression or amplification, one of the most common mechanisms of resistance on third-generation EGFR-TKIs. MET-driven resistance is associated with poor prognosis, and there is a significant unmet need for effective and well-tolerated treatment options in later-line settings. The safety profile for TAGRISSO plus savolitinib was consistent with the known profiles of each medicine, and there were no new safety findings. Among the 46 patients who were rechallenged with TAGRISSO, 11% had recurrence of ILD/pneumonitis. In the 80 TAGRISSO-treated patients, ILD/pneumonitis resolved in 40%, resolved with sequelae in 1.3%, were resolving in 16%, did not resolve in 41%, and resulted in death in 1.3%. For patients receiving TAGRISSO who have not received recent definitive platinum-based CRT, withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Permanently discontinue TAGRISSO if ILD/pneumonitis is confirmed. For patients who have received recent definitive platinum- based CRT with Grade 1 ILD/pneumonitis, continue TAGRISSO or interrupt and restart, as appropriate. Permanently discontinue TAGRISSO in patients diagnosed with Grade =2 ILD/pneumonitis. TAGRISSO can cause heart rate-corrected QT (QTc) interval prolongation. Of the 1,813 TAGRISSO monotherapy-treated patients in clinical trials, 1.1% were found to have a QTc >500 msec, and 4.3% of patients had an increase from baseline QTc >60 msec. Of the 276 patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy in the FLAURA2 study, 1.8% were found to have a QTc >500 msec, and 10.5% of patients had an increase from baseline QTc >60 msec. Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC. Approximately 75% of NSCLC patients are diagnosed with advanced disease. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. Savolitinib also received a conditional approval in China for the treatment of patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification who have failed at least two prior systemic treatments. Savolitinib in combination with TAGRISSO is approved in China for patients with locally advanced or metastatic EGFRm-positive non-squamous NSCLC with MET amplification after disease progression on EGFR-TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO. This was based on results from the global SAVANNAH Phase II trial. TAGRISSO® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including the treatment of central nervous system metastases. TAGRISSO (40 mg and 80 mg QD oral tablets) has been used to treat more than one million patients across its indications worldwide. TAGRISSO is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, adjuvant treatment of early-stage EGFRm NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy. TAGRISSO is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC. There is an extensive body of evidence supporting the use of TAGRISSO in EGFRm NSCLC, and it is the only targeted therapy shown to improve patient outcomes across all stages of the disease. In late-stage disease, TAGRISSO demonstrated improved outcomes as monotherapy in the FLAURA Phase III trial and in combination with chemotherapy in the FLAURA2 Phase III trial. TAGRISSO is also being investigated in this setting in combination with datopotamab deruxtecan-dlnk in the TROPION-Lung14 and TROPION-Lung15 Phase III trials. TAGRISSO also showed improved outcomes in early-stage disease in the NeoADAURA and ADAURA Phase III trials and in locally advanced stages in the LAURA Phase III trial. TAGRISSO is also being investigated in the early-stage adjuvant resectable setting in the ADAURA2 Phase III trial.

U.K. (FTSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

AstraZeneca Demonstrates Statistically Significant and Clinically Meaningful Improvements with TAGRISSO Plus Savolitinib in Saffron Phase III Trial

Now 22% overvalued after recent price rise

Consensus EPS estimates fall by 11%

First half dividend of US$0.38 announced

Emergen-C Partners with Carl Radke’S Soft Bar to Launch Limited-Time Mocktail Experience Showcasing Multi-Benefit Support

Shield Therapeutics plc Appoints Michael Jensen as Chief Financial Officer, Effective 1 September 2026

Futura Medical plc Clears Launch of Eroxon Intense Across European Economic Area and Uk

New major risk - Share price stability

Poolbeg Pharma Receives Notice Of Allowance For POLB 001 Cancer Immunotherapy-Induced CRS Patent In Israel

Sareum Holdings PLC Completes Dosing In Phase 2-Enabling Toxicology Programme for SDC-1801

Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026

Immupharma Reports University of Murcia Research on P140 Peptide in Glioblastoma

New major risk - Shareholder dilution